NDA Accepted for Extended-Release Carbinoxamine Oral Suspension for Allergies

Tris Pharma announced that the FDA has accepted the New Drug Application of its extended-release carbinoxamine oral suspension for the treatment of allergies in children ≥2 years. This formulation utilizes Tris' proprietary OralXR+ technology, a flexible, sustained-release coating that delivers small (about 100 microns) particles that release drug over time.

Carbinoxamine is a mildly sedating antihistamine currently available in immediate-release tablet and oral solution formulations.

For more information call (732) 940-2800 or visit www.trispharma.com.